Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.
Gastroenterology, 2012/10;143(4):913-6.e7.
Vrieze A[1], Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M
Affiliations
PMID: 22728514
Impact factor: 33.883
Abstract
Alterations in intestinal microbiota are associated with obesity and insulin resistance. We studied the effects of infusing intestinal microbiota from lean donors to male recipients with metabolic syndrome on the recipients' microbiota composition and glucose metabolism. Subjects were assigned randomly to groups that were given small intestinal infusions of allogenic or autologous microbiota. Six weeks after infusion of microbiota from lean donors, insulin sensitivity of recipients increased (median rate of glucose disappearance changed from 26.2 to 45.3 μmol/kg/min; P < .05) along with levels of butyrate-producing intestinal microbiota. Intestinal microbiota might be developed as therapeutic agents to increase insulin sensitivity in humans; www.trialregister.nl; registered at the Dutch Trial Register (NTR1776).
MeSH terms
Adult; Alcaligenes faecalis; Bacteroidetes; Blood Glucose; Body Mass Index; Clostridium; Escherichia coli; Eubacterium; Fatty Acids, Volatile; Feces; Humans; Insulin Resistance; Intestine, Small; Male; Metabolic Syndrome; Metagenome; Middle Aged; Oxalobacter formigenes; Statistics, Nonparametric
More resources
EndNote: Download